| 000 | 01554 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250514042041.0 | ||
| 264 | 0 | _c20020920 | |
| 008 | 200209s 0 0 eng d | ||
| 022 | _a1468-201X | ||
| 024 | 7 |
_a10.1136/heart.88.3.234 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _avan Dam, M | |
| 245 | 0 | 0 |
_aLong term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia. _h[electronic resource] |
| 260 |
_bHeart (British Cardiac Society) _cSep 2002 |
||
| 300 |
_a234-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aApolipoproteins B _xblood |
| 650 | 0 | 4 | _aAtorvastatin |
| 650 | 0 | 4 |
_aCholesterol _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeptanoic Acids _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aHyperlipidemias _xblood |
| 650 | 0 | 4 |
_aHyperlipoproteinemia Type III _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPyrroles _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTriglycerides _xblood |
| 700 | 1 | _aZwart, M | |
| 700 | 1 | _ade Beer, F | |
| 700 | 1 | _aSmelt, A H M | |
| 700 | 1 | _aPrins, M H | |
| 700 | 1 | _aTrip, M D | |
| 700 | 1 | _aHavekes, L M | |
| 700 | 1 | _aLansberg, P J | |
| 700 | 1 | _aKastelein, J J P | |
| 773 | 0 |
_tHeart (British Cardiac Society) _gvol. 88 _gno. 3 _gp. 234-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/heart.88.3.234 _zAvailable from publisher's website |
| 999 |
_c12063703 _d12063703 |
||